

Synthesis and Biological Activity of a Focused  
Library of Mitogen-Activated Protein Kinase  
Phosphatase Inhibitors

*And*

Investigation of the Utility of Benzothiazole and 5-  
Methylthiadiazole Sulfonamides as Nitrogen Atom  
Protecting Groups in Asymmetric Addition  
Reactions to Aldimines

David Arnold

4/28/07

Wipf Group: Research Topic Seminar

# Outline for Part 1

- Library Synthesis:

Brief Background


Library Design

Synthetic Routes

Biological Results

# Background: Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) as a Therapeutic Target

- MKP-1 is a dual-specificity phosphatase involved in tightly regulated signaling pathways responsible for cell growth, division and death.




• *Annu. Rev. Pharmacol. Toxicol.* **2005**, *45*, 725


# Background: Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) as a Therapeutic Target

- MKP-1 was initially believed to be a tumor suppressor.
- MKP-1 has been found to be over expressed in prostate, gastric, breast and pancreatic cancer.
- To date, No x-ray crystal structures are available for Structure Activity Relationship (SAR) analysis to aid in inhibitor design.
- Selective and potent MKP-1 inhibitors may lead to therapeutic treatments for cancer.

# Background: Two Known Inhibitors of MKP-1 Previously Discovered by the University of Pittsburgh



Sanguinarine



NU-126


## Comparison of Potency and Selectivity for Sanguinarine and NU-126

### Average $IC_{50} \pm$ S.D. for inhibition of dual-specificity phosphatases

	MKP-1	MKP-3	Cdc25B	PTP1B	VHR
Sanguinarine	$17.3 \pm 1.2 \mu\text{M}$	$>>100$	$57.8 \pm 11.6 \mu\text{M}$	$67.9 \pm 11.7 \mu\text{M}$	$74.0 \pm 5.3 \mu\text{M}$
NU-126	$28.8 \pm 2.9 \mu\text{M}$	$>400$	$>400$	$>100$	$38.1 \pm 2.8 \mu\text{M}$


- *J. Biol. Chem.* **2005**, *280*, 19078.
- *Bioorg. Med. Chem.* **2006**, *14*, 5643.

# Pittsburgh Molecular Libraries Screening Center: High Throughput Screen of 13,309 Compounds for MKP-1 Inhibitors



$$IC_{50} = 19.2 \pm 5.6 \mu\text{M}$$


# Library Design: Retro-Synthesis and Points of Diversification



R<sup>1</sup>: H, CF<sub>3</sub>  
 R<sup>2</sup>: H, CF<sub>3</sub>, Ph, Cyclopropyl, Furyl  
 R<sup>3</sup>: Methyl, Methylcyclopropyl, Isobutyl, Benzyl  
 R<sup>4</sup>: Methyl, Benzyl

Target Library:  
 26 Compounds

# Synthesis of Mono and Bis-Trifluoromethyl Quinolinecarboxylic Acid Sodium Salts




- *Eur. J. Org. Chem.* **2003**, 1576–1588.
- *J. Med. Chem.* **2000**, 35, 359–364.




# Preparation of R<sup>2</sup> = H, Ph, Furyl and Cyclopropyl Quinolinecarboxylic Acid Sodium Salts



- Purchased quinolinecarboxylic acids



- Synthesis of furyl and cyclopropyl quinolinecarboxylic sodium salts




# Synthesis of $N^6$ -[(Dimethylamino)methylene] Protected $N^1$ -Alkylaminouracils




- *J. Org. Chem.* **1986**, *51*, 4180-4185.
- *J. Org. Chem.* **1951**, *16*, 1879-1890.
- *Synthesis*, **2001**, *3*, 478-482.

# Synthesis of $N^1, N^3$ -Dialkyl-6-Aminouracils




# Synthesis of 5-Chloroacetyl-*N*<sup>1</sup>,*N*<sup>3</sup>-Dialkyl-6-aminouracils




- j) R<sup>3</sup> = benzyl, R<sup>4</sup> = Me    k) R<sup>3</sup> = methylcyclopropyl, R<sup>4</sup> = Me  
 l) R<sup>3</sup> = Me, R<sup>4</sup> = benzyl    m) R<sup>3</sup> = Me, R<sup>4</sup> = Me (Purchased)  
 n) R<sup>3</sup> = i-Bu, R<sup>4</sup> = Me (Purchased)

1) Chloroacetic acid  
 Pyr, 95 °C, 1 h  
 2) H<sub>2</sub>O, 50 -> 0 °C



• *Chemistry of Heterocyclic Compounds*, 1978, 443–446.

# Final Compound Library Synthesis



o) R<sup>1</sup> = H, R<sup>2</sup> = CF<sub>3</sub>: 51%  
(DMA-P154)  
p) R<sup>1</sup> = CF<sub>3</sub>, R<sup>2</sup> = CF<sub>3</sub>: 58%  
(DMA-P155)  
q) R<sup>1</sup> = H, R<sup>2</sup> = Ph: 39%  
(DMA-P148)  
r) R<sup>1</sup> = H, R<sup>2</sup> = furan: 54%  
(DMA-P156)  
s) R<sup>1</sup> = H, R<sup>2</sup> = cyclopropyl: 48%  
(DMA-P157)

t) R<sup>1</sup> = CF<sub>3</sub>, R<sup>2</sup> = CF<sub>3</sub>: 55%  
(DMA-P166)  
u) R<sup>1</sup> = H, R<sup>2</sup> = furan: 56%  
(DMA-P165)


v) R<sup>1</sup> = H, R<sup>2</sup> = CF<sub>3</sub>: 62%  
(DMA-P158)  
w) R<sup>1</sup> = CF<sub>3</sub>, R<sup>2</sup> = CF<sub>3</sub>: 53%  
(DMA-P159)  
x) R<sup>1</sup> = H, R<sup>2</sup> = Ph: 47%  
(DMA-P162)  
y) R<sup>1</sup> = H, R<sup>2</sup> = furan: 59%  
(DMA-P160)  
z) R<sup>1</sup> = H, R<sup>2</sup> = cyclopropyl: 50%  
(DMA-P161)

aa) R<sup>1</sup> = H, R<sup>2</sup> = CF<sub>3</sub>: 45%  
(DMA-P145)  
bb) R<sup>1</sup> = CF<sub>3</sub>, R<sup>2</sup> = CF<sub>3</sub>: 56%  
(DMA-P146)  
cc) R<sup>1</sup> = H, R<sup>2</sup> = Ph: 66%  
(DMA-P100)  
dd) R<sup>1</sup> = H, R<sup>2</sup> = H: 74%  
(DMA-P78)  
ee) R<sup>1</sup> = H, R<sup>2</sup> = furan: 70%  
(DMA-P138)  
ff) R<sup>1</sup> = H, R<sup>2</sup> = cyclopropyl: 59%  
(DMA-P140)

gg) R<sup>1</sup> = H, R<sup>2</sup> = CF<sub>3</sub>: 58%  
(DMA-P151)  
hh) R<sup>1</sup> = CF<sub>3</sub>, R<sup>2</sup> = CF<sub>3</sub>: 55%  
(DMA-P152)  
ii) R<sup>1</sup> = H, R<sup>2</sup> = Ph: 60%  
(DMA-P101)  
jj) R<sup>1</sup> = H, R<sup>2</sup> = furan: 61%  
(DMA-P153)  
kk) R<sup>1</sup> = H, R<sup>2</sup> = cyclopropyl: 31%  
(DMA-P149)

## Library Results


- 23 of the target 26 final library analogues were synthesized in yields ranging from 31-74%.
- A total library of 47 compounds was submitted for biological testing against MKP-1.
- None of the 24 uracil or quinoline intermediates tested were found to be biologically active against MKP-1.
- A remake of the original HTS hit showed an approximately three fold loss of potency against MKP-1.




Original HTS Hit:  $IC_{50} = 19.2 \pm 5.6 \mu M$   
Remake:  $IC_{50} = 50 \mu M$

# Library Results


- All of the 23 final library analogues tested showed an  $IC_{50} > 50 \mu\text{M}$  against MKP-3.
- Five analogues showed a potency against MKP-1 comparable to the original hit:




$IC_{50} = 13.4 \mu\text{M}$




$IC_{50} = 16.9 \mu\text{M}$



$IC_{50} = 20.6 \mu\text{M}$



$IC_{50} = 24.6 \mu\text{M}$



$IC_{50} = 28.9 \mu\text{M}$

# Outline for Part 2

- Utility of Benzothiazole (Bts) and 5-Methylthiadiazole (Ths) Sulfonamides as Protecting Groups in the Synthesis of  $\alpha$ -Chiral Amines:

Background

Sulfonamide Synthesis

Benzaldimine Synthesis

Racemic Additions


Asymmetric Additions

Deprotection

Future Directions




# Background: Important Pharamacetucials Containing $\alpha$ -Chiral Amines




Rivastigmine

Treatment for mild to moderate  
dementia resulting from Alzheimer's  
or Parkinson's Disease



Repaglinide

Treatment for type II Diabetes




Taxol

Treatment for cancer


# Background: Organometallic Additions to Aldimines

- Common Aldimines




*J. Org. Chem.* **1990**, 55, 393.

*Synthesis* **1999**, 6, 930.




# Background: Asymmetric Additions of Diethylzinc to N-phosphinoylaldimines

- Addition with a stoichiometric amount of ligand



- *J. Org. Chem.* **1998**, *63*, 2530.



- Copper catalyzed additions



- *J. Am. Chem. Soc.* **2003**, *125*, 14260.



# Background: Asymmetric Additions to N-Sulfonylaldimines

- Copper catalyzed asymmetric addition of  $\text{Et}_2\text{Zn}$  to sulfonylaldimines



- Synlett* **2007**, 1, 19.




- Ligand catalyzed asymmetric additions to heteroaromatic sulfonylaldimines



Nucleophile	Temperature	Yield	ee
$\text{CH}_3\text{MgBr}$	-95 °C	67%	83%
$\text{Et}_2\text{Zn}$	-40 °C	49%	46%


- Tetrahedron Lett.* **2005**, 46, 8941.

# Background: Zr-Zn Transmetalation Followed by Catalytic Asymmetric Addition to Aldehydes and Aldimines




# Background: Introduction of the Benzothiazole (Bts) and 5-Methylthiadiazole (Ths) Sulfonamides as Nitrogen Atom Protecting Groups


## • Protection of Amino Acids



## • Deprotection



- Pg = Bts, Ths
- When Pg = Ts, No deprotection occurred
- >90% yields
- Retention of amino acid chirality




22

• J. Am. Chem. Soc. 1996, 118, 9796


6/22/2007

# Introduction To Research




# Synthesis of Benzothiazole-2-sulfonamides (BtsNH<sub>2</sub>) and 5-Methyl-1,3,4-thidiazole-2-sulfonamides (ThsNH<sub>2</sub>)

- BtsNH<sub>2</sub>:




- ThsNH<sub>2</sub>:






# Preparation of Ths- and Bts-Benzaldimines


- Ths-Benzaldimine



- Bts-Benzaldimine




# Racemic Additions: Lithium Reagents



Lithium Reactions

	<b>Pg</b>	<b>R</b>	<b>Time</b>	<b>Yield</b>
1	Ths	Me	2 h	23%
2	Ths	<i>t</i> -Butyl	2 h	dec.
3	Bts	Me	2 h	dec.

# Racemic Additions: Grignard Additions to Ths-Benzaldimine




## Grignard Reactions

Optimization Reactions					Rec. Yields		
	Solvent	X	R	Time	Temp.	2 Step	1 Step
1	CH <sub>2</sub> Cl <sub>2</sub>	Cl	i-Propyl	2.5 h	-78 °C	45%	X
<b>2</b>	<b>THF</b>	<b>Cl</b>	<b>i-Propyl</b>	<b>2 h</b>	<b>-78 °C</b>	<b>47%</b>	<b>X</b>
3	THF	Cl	i-Propyl	1.5 h	-78 -> rt	15%	X

## Grignard Reactions Using Optimized Conditions

1	THF	Cl	i-Propyl	2 h	-78 °C	46%	58%
2	THF	Br	Ph	2 h	-78 °C	51%	64%
3	THF	Br	Me	2 h	-78 °C	49%	61%
4	THF	Br	Vinyl	2 h	-78 °C	37%	46%
5	THF	Br	1-propynyl	2 h	-78 °C	39%	49%


# Racemic Additions: Grignard Additions to Bts-Benzaldimine



**Grignard Reactions**

	<b>Solvent</b>	<b>X</b>	<b>R</b>	<b>Time</b>	<b>Temp.</b>	<b>Yield</b>
1	THF	Br	Me	2.5 h	-78 °C	87%
2	THF	Cl	i-Propyl	2.5 h	-78 °C	77%
3	THF	Br	Vinyl	3 h	-78 °C	85%
4	THF	Br	1-propynyl	3 h	-78 °C	71%
5	THF	Br	Ph	3 h	-78 °C	77%


# Racemic Additions: Diethylzinc Additions to Bts- and Ths-Benzaldimines



Diethylzinc Reactions


	Pg	Solvent	Eq. $\text{Et}_2\text{Zn}$	Temperature	Time	Yield
1	Ths	10% THF/Toluene	1	rt	2.5 h	46%
2	Ths	THF	1.2	rt	4 h	43%
3	Ths	Toluene	1.2	rt	2.5 h	53%
<b>4</b>	<b>Ths</b>	<b>Toluene</b>	<b>2</b>	<b>rt</b>	<b>2.5 h</b>	<b>70%</b>
5	Ths	Toluene	1	-78 °C	33 h	61%
<b>6</b>	<b>Bts</b>	<b>Toluene</b>	<b>2</b>	<b>rt</b>	<b>4 h</b>	<b>63%</b>
7	Bts	THF	2	rt	4 h	40%
8	Bts	Toluene	2	0 °C	6 h	40%

# Racemic Reactions: Vinylzinc Additions to Bts- and Ths-Benzaldimines



1-Hexyne Derived Vinylzinc Additions


	Aldimine	Eq. Cp <sub>2</sub> ZrHCl	Eq. Me <sub>2</sub> Zn	Solvent	Temp	Time	Yield
1	Ths	1.6	1.5	Toluene 1:1 CH <sub>2</sub> Cl <sub>2</sub>	rt	2.5 h	35%
2	Ths	1.6	1.5	Toluene 1:1 CH <sub>2</sub> Cl <sub>2</sub>	-40 °C	10 h	57%
3	Bts	1.6	1.5	CH <sub>2</sub> Cl <sub>2</sub>	rt	4.5 h	71%




3-Hexyne Derived Vinylzinc Additions

	Aldimine	Eq. Cp <sub>2</sub> ZrHCl	Eq. Me <sub>2</sub> Zn	Solvent	Temp	Time	Yield
1	Ths	1.6	1.5	Toluene 1:1 CH <sub>2</sub> Cl <sub>2</sub>	rt	2 h	47%
2	Bts	1.6	1.5	CH <sub>2</sub> Cl <sub>2</sub>	rt	4.5 h	63% (2 products)

# Asymmetric Reactions: Vinylzinc Additions In the Presence of 2-[(R)-1-(Dimethylamino)ethyl]benzenethiol




• *Org. Lett.* **2002**, *4*, 3619.



**Asymmetric Additions Using 2-[(R)-1-(Dimethylamino)ethyl]benzenethiol Ligand**


	Aldimine	Eq. Cp <sub>2</sub> ZrHCl	Eq. Me <sub>2</sub> Zn	Ligand	Solvent	Temp	Time	Yield	ee
1	Ths	3.2	3	100%	Toluene 1:2 CH <sub>2</sub> Cl <sub>2</sub>	-40 °C	12 h	63%	10 %
2	Ths	1.5	1	15%	Toluene 1:1 CH <sub>2</sub> Cl <sub>2</sub>	-40 °C	15 h	33%	0%
3	Bts	2.5	2.5	100%	CH <sub>2</sub> Cl <sub>2</sub>	-30 °C	20 h	62%	5%
4	Bts	2.5	2.5	100%	Toluene	-30 °C	16 h	80%	3%

# Asymmetric Reactions: Vinylzinc Additions Using a Diverse Set of Ligands




**Asymmetric Additions Using a Diverse Set of Ligands**

	Eq. $\text{Cp}_2\text{ZrHCl}$	Eq. $\text{Me}_2\text{Zn}$	Eq. Ligand	Solvent	Temp	Time	Yield	ee
1	2.5	2.5	100% of <b>1</b>	Toluene	-30 °C	20 h	X	X
2	2.5	2.5	100% of <b>2</b>	Toluene	-30 °C	13 h	84%	1%
3	1.5	1.5	100% of <b>3</b>	Toluene	-30 °C	9 h	13%	3%






# Asymmetric Reactions: Diethylzinc Additions Using $\text{Cu}(\text{OTf})_2$ Catalysis and Me-DuPHOS Derived Ligands




• *J. Am. Chem. Soc.* **2003**, *125*, 14260.




## Copper Catalyzed Reactions

	Pg	% $\text{Cu}(\text{OTf})_2$	% Ligand	Time	Yield	% ee
1	$\text{P}(\text{O})\text{Ph}_2$	6%	3% of Me-DuPHOS monoxide	19 h	86%	97%
2	Bts	10%	5% of Me-DuPHOS	15 h	48%	0%
3	Bts	10%	5% of Me-DuPHOS monoxide	15 h	60%	0%


# Asymmetric Reactions: Diethylzinc Additions Using $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ Catalysis and BINOL Derived Thiophosphoramidate Ligands



• *J. Org. Chem.* **2002**, *67*, 3450.






• *J. Org. Chem.* **1993**, *58*, 1748.




**Copper Catalyzed Reactions**

	Pg	% $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	% Ligand	Time	Yield	% ee
1	Bts	3%	6%	15 h	83%	9%
2	Bts	6%	12%	17 h	85%	11%
3	Bts	25%	50%	16 h	74%	8%
4	Ths	5%	10%	17 h	70%	10%

# Asymmetric Reactions: Synthesis of BINOL Derived Thiophosphoramidate Ligands Using a Variety of Chiral Amines




# Asymmetric Reactions: Diethylzinc Additions Using $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ Catalysis and BINOL Derived Thiophosphoramidate Ligands




**Copper Catalyzed Reactions**

	Addition	% $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	% Ligand	Time	Yield	% ee
1	Aldimine First	5%	10% of <b>1</b>	14 h	76%	5%
2	Aldimine First	5%	10% of <b>2</b>	14 h	83%	7%
3	Aldimine First	25%	50% of <b>2</b>	15 h	83%	12%
4	$\text{Et}_2\text{Zn}$ First	5%	10% of <b>2</b>	15 h	69%	0%




# Synthesis of Trifluoromethyl Hemiaminals



Trifluoromethyl Hemiaminals

	Eq. Ketone	Eq. $\text{Ti(OEt)}_4$	Additive	Temp	Time	$^{19}\text{F}$ NMR % Conversion	Yield
1	3	2	X	rt	4 d	47%	12%
2	2	1.5	X 15%	MW 110 °C	1.5 h	dec.	X
3	2	1.5	DMAP 20%	rt	2 h	60%	Trace
4	2	1.5	DMAP	rt	5 h / 4 d	57%	13%


# Deprotection Reactions: Optimization of Boc Anhydride Conditions for Amine Protection



Optimization of Boc Protection at Room Temp

	Eq. (Boc) <sub>2</sub> O	Base/Catalyst	Solvent	Time	% Yield
1	1.2	10 % DMAP	CH <sub>2</sub> Cl <sub>2</sub>	24 h	11%
2	1.2	2.5 M NaOH	Dioxane	2.75 h	82%
3	1.25	2.5 M NaOH	THF	1 h	89%
<b>4</b>	<b>1.25</b>	<b>1 eq Et<sub>3</sub>N</b>	<b>CH<sub>3</sub>CN</b>	<b>1 h</b>	<b>99%</b>


# Deprotection Reactions: Hypophosphorous Acid



**$\text{H}_3\text{PO}_2$  Deprotection and Boc Protection**

	Deprotection					Protection		
	R	Eq. $\text{H}_3\text{PO}_2$	Additon Time	Time	Workup pH	Eq. $(\text{Boc})_2\text{O}$	Time	% Yield
1	Me	30	3 h	4.5 h	>13	1.25	1 h	84%
2	Me	30	3 h	4.5 h	>13	1.25	1 h	81%
3	Ph	30	3 h	4.5 h	>13	1.25	1 h	83%
4	propynyl	30	3 h	4.5 h	>13	1.25	1 h	88%

# Deprotection Reactions: Samarium(II) Iodide




**$\text{SmI}_2$  Deprotection and Boc Protection**


Deprotection					Protection	
	Pg	Eq. $\text{SmI}_2$	Time	Amine	Conditions	Yield
1	Ths	5	15 h	Crude	Optimized	51%
2	Bts	5	15 h	Crude	Optimized	44%
3	Ths	5	30 h	Crude	Optimized	48%
4	Ths	7	8 h	Crude	Optimized	84%
5	Bts	9	8 h	Crude	Optimized	83%



# Deprotection Reactions: Zn/HOAc and Mercaptoacetic Acid



• *J. Am. Chem. Soc.* **1996**, *118*, 9796.




**Mercaptoacetic Acid Deprotection**

	Base	Eq. HSCH <sub>2</sub> CO <sub>2</sub> H	Solvent	Temp.	Time	<sup>1</sup> H NMR % Conversion
1	Et <sub>3</sub> N	1.3	CH <sub>2</sub> Cl <sub>2</sub>	40 °C	30 h	40%
2	LiOH	1.3	CH <sub>2</sub> Cl <sub>2</sub>	rt	48 h	10%
3	Et <sub>3</sub> N	1.3	THF	66 °C	23 h	45%
4	Et <sub>3</sub> N	1.3	CH <sub>2</sub> Cl <sub>2</sub>	μW 70-80 °C	4 h	50%
5	Et <sub>3</sub> N	3	CH <sub>2</sub> Cl <sub>2</sub>	40 °C	40 h	67%

• *Chem. Commun.* **2004**, 353.


# Future Directions

- Increase substrate scope



Pg = Bts, Ths

- Continue to screen ligands and catalytic organometallic conditions to Improve the enantiomeric excess of the aforementioned reactions.



# Acknowledgements

Dr. Wipf

Caleb Foster

Donna M. Huryn

John S. Lazo

Paul A. Johnston

NSF

The Wipf Group

THANK YOU!